Lumos Pharma, Inc. (LUMO) Tops Q1 EPS by 68c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q1 EPS of ($0.14), $0.68 better than the analyst estimate of ($0.82).

“This has been an exciting and busy time for Lumos Pharma,” commented Rick Hawkins, Chairman, CEO and President. “With the recent close of our merger, the Company continues to execute its strategy to develop its oral therapeutic candidate, LUM-201, for pediatric growth hormone deficiency. Furthermore, we are now engaging in activities that we hope will lead to the expansion of our pipeline through the licensure of other rare disease assets. While we acknowledge that the worldwide coronavirus pandemic will adversely impact the conduct of our Phase 2b clinical trial, with our strong balance sheet and expected non-dilutive funds from the monetization of our priority review voucher, we believe Lumos Pharma is well positioned to execute on our clinical and business development plans.”

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• Golden Spike Resources plans name change, share consolidation and C$500K raise
• NNN REIT adds two directors amid board succession planning